Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
View ORCID ProfileRaburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
doi: https://doi.org/10.1101/2021.12.23.21267374
Raburn Mallory
Novavax, Inc
M.D.Neil Formica
Novavax, Inc
M.B.B.S.Susan Pfeiffer
Novavax, Inc
P.A-C.Bethanie Wilkinson
Novavax, Inc
Ph.D.Alex Marcheschi
Novavax, Inc
Pharm.D.Gary Albert
Novavax, Inc
M.S.Heather McFall
Novavax, Inc
M.S.Michelle Robinson
Novavax, Inc
M.P.H.Joyce S. Plested
Novavax, Inc
Ph.D.Mingzhu Zhu
Novavax, Inc
Ph.D.Shane Cloney-Clark
Novavax, Inc
B.Sc.Bin Zhou
Novavax, Inc
Ph.D.Gordon Chau
Novavax, Inc
M.S.Andreana Robertson
Novavax, Inc
M.S.Sonia Maciejewski
Novavax, Inc
Ph.D.Gale Smith
Novavax, Inc
Ph.D.Nita Patel
Novavax, Inc
Ph.D.Gregory M. Glenn
Novavax, Inc
M.D.Filip Dubovsky
Novavax, Inc
M.D.Novavax, Inc
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
Data Availability Data Sharing Statement will be available with the full text of this article upon publication.
Posted December 25, 2021.
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
Raburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
medRxiv 2021.12.23.21267374; doi: https://doi.org/10.1101/2021.12.23.21267374
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
Raburn Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Gale Smith, Nita Patel, Gregory M. Glenn, Filip Dubovsky, for the Novavax Inc. 2019nCoV-101 Study Group
medRxiv 2021.12.23.21267374; doi: https://doi.org/10.1101/2021.12.23.21267374
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12229)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2658)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3883)
- Nursing (209)
- Nutrition (577)
- Oncology (2031)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6529)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (410)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)